MedTrace Logo

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

NCT00902928 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1992

Last updated 2015-10-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.

Conditions

  • Venous Thromboembolism
  • Arthroplasty, Replacement, Hip

Interventions

DRUG

YM150

oral

DRUG

enoxaparin

SC injection

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Europe B.V.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-06-30
Completion
2010-08-31

Countries

  • United States
  • Australia
  • Austria
  • Bosnia and Herzegovina
  • Brazil
  • Canada
  • Colombia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902928 on ClinicalTrials.gov